Cocrystal Pharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$9.0M | -$17.9M | -$18.6M | -$38.8M | -$14.2M |
| Operating expenses | $9.0M | $17.9M | $18.6M | $38.8M | $14.2M |
| Cash from operations | -$8.2M | -$16.5M | -$14.7M | -$21.4M | -$12.7M |
| Capital expenditure | $12,000 | $8,000 | $118,000 | $74,000 | $52,000 |
| Free cash flow | -$8.2M | -$16.5M | -$14.8M | -$21.5M | -$12.8M |
| Impairments | — | — | — | $19.1M | — |
| Total assets | $9.7M | $13.5M | $31.3M | $40.8M | $79.4M |
| Total liabilities | $3.4M | $3.9M | $4.9M | $1.3M | $1.8M |
Shares outstanding 13.8M
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.